Brokerages predict that Minerva Neurosciences, Inc (NASDAQ:NERV) will report ($0.43) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have provided estimates for Minerva Neurosciences’ earnings. Minerva Neurosciences reported earnings of ($0.27) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 59.3%. The business is expected to report its next quarterly earnings report on Monday, March 12th.
According to Zacks, analysts expect that Minerva Neurosciences will report full year earnings of ($1.28) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the business will post earnings of ($1.50) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that cover Minerva Neurosciences.
Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter. During the same period in the prior year, the firm earned ($0.24) earnings per share.
Shares of Minerva Neurosciences (NASDAQ NERV) opened at $6.55 on Friday. Minerva Neurosciences has a 1-year low of $4.80 and a 1-year high of $11.20. The company has a market capitalization of $251.55, a price-to-earnings ratio of -5.90 and a beta of 1.53.
In other Minerva Neurosciences news, CFO Geoff Race sold 5,829 shares of the business’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $5.79, for a total value of $33,749.91. Following the sale, the chief financial officer now directly owns 197,698 shares of the company’s stock, valued at $1,144,671.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 12,590 shares of company stock worth $73,073 over the last three months. Corporate insiders own 21.60% of the company’s stock.
Several large investors have recently made changes to their positions in the company. FMR LLC lifted its holdings in shares of Minerva Neurosciences by 13.7% during the second quarter. FMR LLC now owns 5,660,794 shares of the biopharmaceutical company’s stock valued at $50,098,000 after purchasing an additional 680,000 shares in the last quarter. Franklin Resources Inc. lifted its holdings in shares of Minerva Neurosciences by 39.0% during the second quarter. Franklin Resources Inc. now owns 1,158,100 shares of the biopharmaceutical company’s stock valued at $10,249,000 after purchasing an additional 325,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Minerva Neurosciences by 14.4% during the second quarter. Vanguard Group Inc. now owns 1,074,239 shares of the biopharmaceutical company’s stock valued at $9,507,000 after purchasing an additional 134,942 shares in the last quarter. Sphera Funds Management LTD. lifted its holdings in shares of Minerva Neurosciences by 31.9% during the third quarter. Sphera Funds Management LTD. now owns 625,000 shares of the biopharmaceutical company’s stock valued at $4,750,000 after purchasing an additional 151,231 shares in the last quarter. Finally, JPMorgan Chase & Co. bought a new position in shares of Minerva Neurosciences during the third quarter valued at $2,835,000. 73.68% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/19/0-43-earnings-per-share-expected-for-minerva-neurosciences-inc-nerv-this-quarter-2.html.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.